Stockreport

Erasca Reports Third Quarter 2024 Business Updates and Financial Results

Erasca, Inc.  (ERAS) 
PDF Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected i [Read more]